Live Breaking News & Updates on Prostate Cancer Foundation Scientific

Stay updated with breaking news from Prostate cancer foundation scientific. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 30th Annual Prostate Cancer Foundation Scientific Retreat

ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 30th Annual Prostate Cancer Foundation Scientific Retreat
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United States , British Columbia , Andrew Laccetti , David Parkinson , Drug Administration , Prostate Cancer Foundation Scientific , Pharma Inc , Memorial Sloan Kettering Cancer Center , Prostate Cancer Foundation Scientific Retreat , Enz Alone , Metastatic Castration Resistant Prostate Cancer , Current Phase , Memorial Sloan Kettering Cancer , Fast Track , Private Securities Litigation Reform Act ,

ESSA Pharma Inc. Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 30th Annual Prostate Cancer Foundation Scientific Retreat

ESSA Pharma Inc. announced the presentation of updated dose escalation data from its Phase 1/2 study evaluating masofaniten in combination with enzalutamide at the 30th Annual Prostate Cancer. ....

Andrew Laccetti , Prostate Cancer Foundation Scientific , Drug Administration , Memorial Sloan Kettering Cancer Center , Essa Pharma Inc , Enz Alone , Metastatic Castration Resistant Prostate Cancer , Current Phase , Presenting Author , Fast Track ,

ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 30th Annual Prostate Cancer Foundation Scientific Retreat

/PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for. ....

United States , British Columbia , David Parkinson , Andrew Laccetti , Drug Administration , Memorial Sloan Kettering Cancer Center , Pharma Inc , Prostate Cancer Foundation Scientific , Prostate Cancer Foundation Scientific Retreat , Enz Alone , Metastatic Castration Resistant Prostate Cancer , Current Phase , Memorial Sloan Kettering Cancer , Fast Track , Private Securities Litigation Reform Act ,

ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 30th Annual Prostate Cancer Foundation Scientific Retreat

Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in patients with mCRPC
Across all cohorts of patients including those recently. ....

British Columbia , United States , Andrew Laccetti , David Parkinson , Prostate Cancer Foundation Scientific , Drug Administration , Memorial Sloan Kettering Cancer Center , Pharma Inc , Prostate Cancer Foundation Scientific Retreat , Enz Alone , Metastatic Castration Resistant Prostate Cancer , Current Phase , Fast Track , Private Securities Litigation Reform Act , Canada Newswire ,

ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 30th Annual Prostate Cancer Foundation Scientific Retreat

Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in patients with mCRPC
Across all cohorts of patients including those recently. ....

United States , British Columbia , Andrew Laccetti , David Parkinson , Drug Administration , Prostate Cancer Foundation Scientific , Pharma Inc , Memorial Sloan Kettering Cancer Center , Prostate Cancer Foundation Scientific Retreat , Enz Alone , Metastatic Castration Resistant Prostate Cancer , Current Phase , Memorial Sloan Kettering Cancer , Fast Track , Private Securities Litigation Reform Act ,